Browse News
Filter News
Found 285 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Limb-Girdle Muscular Dystrophy Leaders Advance Collaborative Dialogue to Accelerate Drug Development to Address the Urgent Unmet Need in Limb-Girdle Muscular Dystrophy
2/27/2024
On February 8, 2024, The Speak Foundation, a patient-led 501(c)(3) organization for Limb-Girdle Muscular Dystrophy (LGMD), convened a multi-stakeholder LGMD Scientific Workshop in Rockville, Maryland.
-
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
1/24/2024
Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market
-
San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry
1/12/2024
Every January, the global medical health and financial investment sectors turn their focus to San Francisco.
-
CardioFocus Acquires Electrophysiology Division of Galvanize Therapeutics
1/11/2024
CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced the acquisition of Galvanize Therapeutics' Electrophysiology Technology division.
-
ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery
12/14/2023
ROME Therapeutics announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase.
-
Galvanize Therapeutics Announces Promising Data on the Aliya™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer
11/6/2023
Galvanize Therapeutics, Inc. unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SITC) conference.
-
Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung
9/20/2023
Galvanize Therapeutics, Inc. today announced the treatment of the first patient in the AFFINITY clinical study.
-
Oviva Therapeutics Appoints Rachel Rimsky Rubin as Chief Operating Officer
9/12/2023
Oviva Therapeutics today announced the appointment of Rachel Rimsky Rubin as its new Chief Operating Officer (COO), effective as of September 5, 2023.
-
Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials
9/7/2023
Cerba HealthCare, a leading global player in medical diagnosis, announced it has acquired CIRION BIOPHARMA RESEARCH INC, a Canadian-controlled private company highly recognized for its integrated bioanalytical and global central laboratory services.
-
Foundery Launches Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies
8/22/2023
Foundery, a biotechnology venture studio focused on translating immunology discoveries into drug candidates, announced an initial closing of its inaugural fund, Foundery I, LP, with total capital commitments and contributed assets as of the closing equal to $29.6 million.
-
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
8/21/2023
GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation.
-
GILEAD SCIENCES AND IAS – THE INTERNATIONAL AIDS SOCIETY – HONOUR HEALTHCARE PROVIDERS GLOBALLY WHO CHAMPION STIGMA-FREE HIV SERVICES
7/5/2023
IAS – the International AIDS Society – in partnership with Gilead Sciences, announced 18 Champions of the 2023 Me and My Healthcare Provider (MMHCP) campaign from Brazil, Hong Kong, Mexico and Taiwan.
-
Hesperos Scientists Publish a New Study in Scientific Reports Titled: "Development of a Human Malaria-on-a-Chip Disease Model for Drug Efficacy and Off-Target Toxicity Evaluation"
7/5/2023
A team of dedicated researchers at the human-on-a-chip company Hesperos, Inc. have taken on the challenge to investigate new ways to combat this disease in collaboration with the Medicines for Malaria Venture (MMV).
-
Galvanize Therapeutics Completes Enrollment in Pivotal Trial of RheOx® System for Chronic Bronchitis
6/19/2023
Galvanize Therapeutics, Inc. has completed enrollment in the RheSolve pivotal trial evaluating the RheOx ® Bronchial Rheoplasty System as a treatment for chronic bronchitis symptoms.
-
Galvanize Announces License Agreement and Partnership with Energenx Medical for its Technologies in China
5/30/2023
Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies for COPD, solid tumors and cardiac arrhythmias, announced today that the company has signed an exclusive license agreement with Energenx Medical, Ltd to develop and commercialize its products in Mainland China, Hong Kong, Taiwan, and Macau.
-
After 12 years on the market, the FDA announced it has withdrawn its previous approval for the only drug on the market to prevent preterm birth, Covis Pharma’s Makena.
-
FDA Commissioner and Chief Scientist Announce Decision to Withdraw Approval of Makena
4/6/2023
Today, the U.S. Food and Drug Administration announced the final decision to withdraw approval of Makena—a drug that had been approved under the accelerated approval pathway.
-
Canadian Cancer Society announces details of historic research funding program to transform low-survival cancers
3/31/2023
New research grants announced by the Canadian Cancer Society in partnership with Brain Canada, the Canadian Institutes of Health Research, the Cancer Research Society and the Lotte & John Hecht Memorial Foundation are bringing together high-performance, interdisciplinary teams to accelerate progress against 6 low-survival cancers.
-
New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors
3/7/2023
New interventional oncology data from Galvanize Therapeutics demonstrate positive pre-clinical and early clinical study results using the Aliya™ Pulsed Electric Field (PEF) system.